Difficult to obtain antibody drugs are now available as research consumables
Tremfya® The reference Guselkumab Drug
Divided into tubes
Guselkumab Drug Aliquots
Aliquots of the reference drug Guselkumab are now available as research consumables.
Guselkumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Guselkumab drug can be ordered at the same time. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug. Are you thinking why buy aliquots?
What our clients say
“Evidentic’s Drug aliquots helped us to ascertain the efficacy of our novel molecule [in comparison to commercial therapeutic antibody] which supported our fundraising efforts. ”
Evidentic drug aliquots have helped us speed up our antibody characterization assays and selection of clonal cell lines. An easy and reliable source!
”Evidentic can supply different batches of reference products for precilinical research.The quick access to the on-stock batches allows for adhoc ordering, keeps costs down and makes a headstart possible!”
“Evidentic is a new source of cost-efficient therapeutic mAbs for our immonassays. And easy to order!”
“We develop innovative and biosimilar mAbs for a global market. Evidentic’s aRMPs are a great source of cost-efficient reference products for our research and development program.”
“Evidentic was the only source that offered small aliquots of original therapeutic mAbs at an affordable price range. The aliquots came in an easy-to-use-and-store format that was apt for my research purpose.”
Cetuximab / Erbitux
|API type||Cetuximab is a chimeric monoclonal IgG1antibody produced in a mammalian cell line (Sp2/0) by recombinant DNA technology|
|Pharmacotherapeutic group||Antineoplastic agents, monoclonal antibodie|
|Target of antibody||EGFR; Synonyms: C-erb, CG10079, D-EGFR, D-Egf, DEGFR, DER, DER flb, DER/EGFR, DER/faint little ball, DER/top, DER/torpedo, DER1, DEgfr, Degfr, Der, DmHD-33, Dmel\\CG10079, EFG-R, EGFr, EGfr, EK2-6, Egf, Egf-r, EgfR, El, Elp, Elp-1, Elp-B1, Elp-B1RB1, HD-33, TOP, Torpedo/DER, Torpedo/Egfr, c-erbB, d-egf-r, dEGFR, dEGFR1, dEgfr, der, egfr, flb, l(2)05351, l(2)09261, l(2)57DEFa, l(2)57EFa, l(2)57Ea, mor1, top, top/DER, top/flb, torpedo/Egfr, torpedo/egfr, EGFR12, EGFR15, egfr1, Erbb2, ERBB, ERBB1, HER1, PIG61, mENA, ErbB-1, Errp, 9030024J15Rik, AI552599, Erbb, Errb1, Wa5, wa-2, wa2|
(Mechanism of action; Source EMA document)
|Cetuximab is a chimeric monoclonal IgG1 antibody that is specifically directed against the epidermal growth factor receptor (EGFR).|
EGFR signalling pathways are involved in the control of cell survival, cell cycle progression, angiogenesis, cell migration and cellular invasion/metastasis.
Cetuximab binds to the EGFR with an affinity that is approximately 5- to 10-fold higher than that of endogenous ligands. Cetuximab blocks binding of endogenous EGFR ligands resulting in inhibition of the function of the receptor. It further induces the internalisation of EGFR, which can lead to downregulation of EGFR. Cetuximab also targets cytotoxic immune effector cells towards EGFRexpressing tumour cells (antibody dependent cell-mediated cytotoxicity, ADCC).
Cetuximab does not bind to other receptors belonging to the HER family. The protein product of the proto-oncogene RAS (rat sarcoma) is a central down-stream signal transducer of EGFR. In tumours, activation of RAS by EGFR contributes to EGFR-mediated increased proliferation, survival and the production of pro-angiogenic factors.
RAS is one of the most frequently activated family of oncogenes in human cancers. Mutations of RAS genes at certain hot-spots on exons 2, 3 and 4 result in constitutive activation of RAS proteins independently of EGFR signaling.
|Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)||In both in vitro and in vivo assays, cetuximab inhibits the proliferation and induces apoptosis of human tumour cells that express EGFR. In vitro cetuximab inhibits the production of angiogenic factors by tumour cells and blocks endothelial cell migration. In vivo cetuximab inhibits expression of angiogenic factors by tumour cells and causes a reduction in tumour neo-vascularisation and metastasis.|
|Original license holder|
|Marketing authorisation numbers||EU/1/04/281/003|
|Marketing authorisation holder||Merck KGaA|
|Name of the manufacturer of the biological active substance||Merck KGaA|
Frankfurter Straße 250
Boehringer Ingelheim Pharma GmbH & Co
Birkendorfer Str. 65
|Name and address of the manufacturer(s) responsible for batch release|
|Max shelf life||48 months|
|Storage conditions||2°C – 8°C|
|List of excipients||Sodium chloride|
Citric acid monohydrate Sodium hydroxide
Water for injections